EGFR and non-small cell lung carcinoma: As the clinical experience with mutant active ERBB1 in NSCLC developed, it was noted that patients who successfully received erlotinib/gefitinib mono-therapy would develop drug resistance ~6-18 months after the initiation of treatment.